BeiGene Wins Patent Battle, Generic Drug Launch Delayed Until 2037

On November 19, 2024, BeiGene announced that it had reached a settlement agreement with pharmaceutical company MSN on a patent dispute related to Zeebutinib. Under the agreement, the State of BeiGene grants MSN the rights to sell generic versions of Zeebutinib in the U.S. market, provided that the implementation of such rights is not earlier than June 15, 2037. This date extends Zeebutinib's patent protection by more than three years.

Zebutinib, BeiGene's core product, generated nearly $1.3 billion in revenue in 2023, accounting for more than 50% of the company's total revenue. Given the importance of the drug, several generic drug companies have shown strong interest. Both Sandoz and MSN filed generic marketing applications with the US Food and Drug Administration (FDA) and challenged the validity of some of the Zbrutinib patents. However, the two companies did not challenge Zeebutinib's patent on the main ingredient.

In response, BeiGene took legal action. On March 8 of this year, BeiGene filed a patent infringement lawsuit in the United States against Sandoz and MSN, claiming that the Simplified New Drug Application (ANDA) filed by the two companies infringes the patent rights of Zeebutinib, and seeking a permanent injunction to prevent Sandoz and MSN from commercializing the generic drug before Zeebutinib's patent expires.

In the end, both pharmaceutical companies settled with BeiGene. BeiGene had previously reached a joint agreement with Sandoz to withdraw a patent lawsuit against Sandoz for selling generic versions of Zbutinib. With the settlement agreement between MSN and BeiGene, all patent litigation against generic Zeebutinib has been resolved, and the competitive threat from generic drugs has been temporarily alleviated.